Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ALZN002
Therapeutic Area : Neurology
Study Phase : IND Enabling
Recipient : Alzamend Neuro
Deal Size : Undisclosed
Deal Type : Partnership
Details : ALZN002 is a proprietary active immunotherapy product. It consists of autologous DCs, which are activated WBCs taken from each individual patient that are then engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.
Brand Name : ALZN002
Molecule Type : Vaccine
Upfront Cash : Undisclosed
January 04, 2023
Lead Product(s) : ALZN002
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Recipient : Alzamend Neuro
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Allogeneic Bone Marrow-derived Medicinal Signaling Cells
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Longeveron
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of adult donors. Longeveron is advancing Lomecel-B through clinical trials in 3 indications: Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and...
Brand Name : Lomecel-B
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 10, 2022
Lead Product(s) : Allogeneic Bone Marrow-derived Medicinal Signaling Cells
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Longeveron
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride,EDTA acid,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Citius Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
Details : Mino-Lok (minocycline) is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs).
Brand Name : Mino-Lok
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 06, 2022
Lead Product(s) : Minocycline Hydrochloride,EDTA acid,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Citius Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mesenchymal Stem Cells
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Therapeutic Solutions
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JadiCell (mesenchymal stem cells), was shown to be 100% effective in saving the lives of COVID-19 patients under age of 85 in a double-blind, randomized, placebo controlled clinical trial with patients in the ICU on a ventilator.
Brand Name : JadiCell
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 02, 2022
Lead Product(s) : Mesenchymal Stem Cells
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Therapeutic Solutions
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?